Disrupting TNF signaling in pancreatic cancer: A phase I/II clinical study in patients with advanced disease.

被引：0
|
作者：
Kosuri, KV [1 ]
Bekaii-Saab, T [1 ]
Bender, J [1 ]
Criswell, T [1 ]
Kane, Y [1 ]
Chidiac, T [1 ]
Young, D [1 ]
Guttridge, D [1 ]
Caligiuri, M [1 ]
Villalona-Calero, M [1 ]
机构：
[1] Ohio State Univ, James Carter Ctr, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：333S / 333S
页数：1
相关论文
共 50 条
  • [1] Disrupting Cytokine Signaling in Pancreatic Cancer A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease
    Wu, Christina
    Fernandez, Soledad A.
    Criswell, Tamara
    Chidiac, Tarek A.
    Guttridge, Denis
    Villalona-Calero, Miguel
    Bekaii-Saab, Tanios S.
    PANCREAS, 2013, 42 (05) : 813 - 818
  • [2] Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy
    Izzo, Francesco
    Granata, Vincenza
    Fusco, Roberta
    D'Alessio, Valeria
    Petrillo, Antonella
    Lastoria, Secondo
    Piccirillo, Mauro
    Albino, Vittorio
    Belli, Andrea
    Tafuto, Salvatore
    Avallone, Antonio
    Patrone, Renato
    Palaia, Raffaele
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 18
  • [3] Phase II study of gemcitabine in patients with advanced pancreatic cancer
    Carmichael, J
    Fink, U
    Russell, RCG
    Spittle, MF
    Harris, AL
    Spiessi, G
    Blatter, J
    BRITISH JOURNAL OF CANCER, 1996, 73 (01) : 101 - 105
  • [4] Ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
    Gjertsen, M
    Bakka, A
    Soreide, O
    Thorsby, E
    Gaudernack, G
    2ND WORLD CONGRESS - INTERNATIONAL HEPATO-PANCREATO-BILIARY ASSOCIATION, VOL II: BILIARY-PANCREAS, 1996, : 1121 - 1125
  • [5] Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer
    Epelbaum, R.
    Vizel, B.
    Bar-Sela, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
    Chan, Emily
    Chiorean, E. Gabriela
    O'Dwyer, Peter J.
    Gabrail, Nashat Y.
    Alcindor, Thierry
    Potvin, Diane
    Chao, Richard
    Hurwitz, Herbert
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (02) : 355 - 364
  • [7] Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
    Emily Chan
    E. Gabriela Chiorean
    Peter J. O’Dwyer
    Nashat Y. Gabrail
    Thierry Alcindor
    Diane Potvin
    Richard Chao
    Herbert Hurwitz
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 355 - 364
  • [8] A phase II study of gastrimmune in advanced pancreatic cancer
    Brett, BT
    Smith, SC
    Bouvier, CV
    Michaeli, D
    Hochhauser, D
    Davidson, BR
    Kurzawinski, TR
    Watkinson, T
    Pounder, RE
    Caplin, ME
    GUT, 2000, 46 : A79 - A79
  • [9] Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer
    Kim, TW
    Kang, HJ
    Ahn, JH
    Lee, K
    Chang, HM
    Kang, YK
    Lee, JS
    ACTA ONCOLOGICA, 2002, 41 (7-8) : 689 - 694
  • [10] Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer
    Cartwright, TH
    Cohn, A
    Varkey, JA
    Chen, YM
    Szatrowski, TP
    Cox, JV
    Schulz, JJ
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 160 - 164
12345